CoChat
Sign Up
Cited by 1,392Pharmacology and Obesity TreatmentCannabis and Cannabinoid ResearchAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Open access
Després, Jean-Pierre, Golay, Alain, Sjöström, Lars·2005·New England Journal of Medicine
DOI 10.1056/nejmoa044537
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are overweight or obese and have dyslipidemia. METHODS: We randomly assigned 1036 overweight or obese patients (body-mass index [the weight in kilograms divided by the square of the height in meters], 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men) to double-blinded therapy with either placebo or rimonabant at a dose of 5 mg or 20 mg daily for 12 months in addition to a hypocaloric diet. RESULTS: The rates of completion of the study were 62.6 percent, 60.3 percent, and 63.9 percent in the placebo group, the group receiving 5 mg of rimonabant, and the group receiving 20 mg of rimonabant, respectively. The most frequent adverse events resulting in discontinuation of the drug were depression, anxiety, and nausea. As compared with placebo, rimonabant at a dose of 20 mg was associated with a significant (P<0.001) mean weight loss (repeated-measures method, -6.7+/-0.5 kg, and last-observation-carried-forward analyses, -5.4+/-0.4 kg), reduction in waist circumference (repeated-measures method, -5.8+/-0.5 cm, and last-observation-carried-forward analyses, -4.7+/-0.5 cm), increase in HDL cholesterol (repeated-measures method, +10.0+/-1.6 percent, and last-observation-carried-forward analyses, +8.1+/-1.5 percent), and reduction in triglycerides (repeated-measures method, -13.0+/-3.5 percent, and last-observation-carried-forward analyses, -12.4+/-3.2 percent). Rimonabant at a dose of 20 mg also resulted in an increase in plasma adiponectin levels (repeated-measures method, 57.7 percent, and last-observation-carried-forward analyses, 46.2 percent; P<0.001), for a change that was partly independent of weight loss alone. CONCLUSIONS: Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa044537

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. 10.2337/diabetes.46.10.1594 · DOI

Cited by

Sorted by citations

See all 1,392

Related

See all

Metadata

Authors
Després, J.-P., Golay, A., & Sjöström, L.
Affiliations
  • Université Laval (CA)
  • University Hospital of Geneva (CH)
  • Sahlgrenska University Hospital (SE)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2005-11-17
Volume
353
Issue
20
Pages
2121-2134
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa044537
OpenAlex
W2087587748
Cited by
1,392
References
38
Citations by year
2026: 17 · 2025: 19 · 2024: 18 · 2023: 26 · 2022: 20 · 2021: 28 · 2020: 27 · 2019: 26 · 2018: 32 · 2017: 24 · 2016: 25 · 2015: 34 · 2014: 31 · 2013: 53 · 2012: 63
FWCI
138.02
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
rimonabant, cannabinoid-1 receptor antagonist, dyslipidemia, overweight, obesity, weight loss, adiponectin, HDL cholesterol, triglycerides, waist circumference, hypocaloric diet, cardiovascular risk factors, dose comparison, body mass index, lipid-lowering therapy
MeSH terms
Rimonabant, Adult, Aged, Blood Glucose, Cholesterol, Double-Blind Method, Female, Humans, Insulin, Male, Middle Aged, Obesity, Piperidines, Pyrazoles, Risk Factors, Triglycerides, Weight Loss, Anti-Obesity Agents, Leptin, Metabolic Syndrome, Dyslipidemias, Overweight, Adiponectin, Cannabinoid Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review